Up
hist161065Report received from Agency, January 3, 2023.
hist161244Referred to the committee on Licensing, Constitution and Federalism, January 13, 2023.
Senate Clearinghouse Rule 22-032
Relating to scheduling Serdexmethylphenidate.
Submitted by the Controlled Substances Board.
hist161064Report received from Agency, January 3, 2023.
hist161245Referred to the committee on Health, January 13, 2023.
Senate Clearinghouse Rule 22-033
Relating to scheduling ten (10) fentanyl related substances.
Submitted by the Controlled Substances Board.
hist161063Report received from Agency, January 3, 2023.
hist161246Referred to the committee on Health, January 13, 2023.
Senate Clearinghouse Rule 22-034
Relating to scheduling Alfaxalone.
Submitted by the Controlled Substances Board.
hist161062Report received from Agency, January 3, 2023.
hist161247Referred to the committee on Health, January 13, 2023.
Senate Clearinghouse Rule 22-035
Relating to Excluding 6-beta-Naltrexol.
Submitted by the Controlled Substances Board.
hist161061Report received from Agency, January 3, 2023.
hist161248Referred to the committee on Health, January 13, 2023.
Senate Clearinghouse Rule 22-036
Relating to scheduling Fospropofol.
Submitted by the Controlled Substances Board.
hist161060Report received from Agency, January 3, 2023.
hist161249Referred to the committee on Health, January 13, 2023.
Senate Clearinghouse Rule 22-037
Relating to scheduling Embutramide.
Down